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The neuroactive steroid estradiol reduces reactive astroglia after
brain injury by mechanisms similar to those involved in the
regulation of reactive gliosis by endocannabinoids. In this study, we
have explored whether cannabinoid receptors are involved in the
effects of estradiol on reactive astroglia. To test this hypothesis,
the effects of estradiol, the cannabinoid CB1 antagonist/inverse
agonist AM251, and the cannabinoid CB2 antagonist/inverse
agonist AM630 were assessed in the cerebral cortex of male rats
after a stab wound brain injury. Estradiol reduced the number of
vimentin immunoreactive astrocytes and the number of glial
fibrillary acidic protein immunoreactive astrocytes in the proximity
of the wound. The effect of estradiol was significantly inhibited by
the administration of either CB1 or CB2 receptor antagonists. The
effect of estradiol may be in part mediated by alterations in
endocannabinoid signaling because the hormone increased in the
injured cerebral cortex the messenger RNA levels of CB2 receptors
and of some of the enzymes involved in the synthesis and
metabolism of endocannabinoids. These findings suggest that
estradiol may decrease reactive astroglia in the injured brain by
regulating the activity of the endocannabinoid system.
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Introduction
Hormones of the gonadal axis regulate the expression of the
enzymes involved in the synthesis and metabolism of endo-
cannabinoids in different peripheral tissues (MacCarrone et al.
2000; Xiao et al. 2002; Guo et al. 2005; Grimaldi et al. 2009;
Ribeiro et al. 2009). In addition, gonadal hormones, including
estradiol, affect the activity of the endocannabinoid system in
the brain and the pituitary (Rodrı´guez de Fonseca et al. 1994;
Gonza´lez et al. 2000; Corchero et al. 2001; Bradshaw et al. 2006;
Nguyen and Wagner 2006; Hill et al. 2007). In turn,
cannabinoids interfere with the activity of the hypothalamo-
pituitary gonadal axis at different levels, having a negative
impact on sexual behavior and sexual motivation (Ferrari et al.
2000; Lo´pez 2010; Lo´pez et al. 2010). In addition, both,
cannabinoids and estradiol, have antagonistic actions in the
control of nonreproductive functions, including cognition
(Daniel et al. 2002) and energy homeostasis (Kellert et al.
2009), while estradiol enhances antinociceptive effects of
cannabinoids (Craft and Leitl 2008) and may regulate emotional
behavior through an endocannabinoid mechanism (Hill et al.
2007).
Both cannabinoids (Panikashvili et al. 2001; van der Stelt and
Di Marzo 2005; Mechoulam and Shohami 2007; Sagredo et al.
2007; Galve-Roperh et al. 2008; Correa, Mestre, et al. 2009) and
estradiol (Bourque et al. 2009; DonCarlos et al. 2009; Pike et al.
2009; Simpkins et al. 2009; Suzuki et al. 2009) are neuro-
protective in different animal models of neurodegenerative
diseases. However, the possible interactions of cannabinoids
and estrogens on neuroprotection have not been sufﬁciently
explored. Nevertheless, a recent study has shown that neuro-
protective actions of estradiol, in a model of focal cerebral
ischemia, are associated to the downregulation of the striatal
levels of the endocannabinoid anandamide (AEA), which are
increased after ischemia (Amantea et al. 2007). This suggests
that endocannabinoids and estrogens may interact in the
promotion of neuroprotection.
Glial cells are involved in the neuroprotective actions of
cannabinoids and estrogenic compounds. Cannabinoids are
known to regulate inﬂammation in the central nervous system
acting on glial and endothelial cells (Eljaschewitsch et al. 2006;
Panikashvili et al. 2006; Are´valo-Martı´n et al. 2008; Correa,
Mestre, et al. 2009; De Filippis et al. 2009; Mestre et al. 2009).
For instance, AEA, via the activation of CB1 receptors, enhances
the synthesis of the cytokine interleukin (IL)-6 and reduces
the synthesis of the proinﬂammatory cytokine tumor necrosis
factor (TNF) a in Theiler’s virus-infected astrocytes (Molina-
Holgado et al. 1997, 1998). In addition, AEA inhibits the release
of nitric oxide by astrocytes exposed to lipopolysaccharide
(LPS) (Molina-Holgado, Molina-Holgado, et al. 2002). Activation
of CB1 receptors also inhibits nitric oxide release by C6 rat
glioblastoma cells exposed to neurotoxic stimuli (Esposito et al.
2001, 2002) and decreases amyloid beta--induced reactive
astrogliosis, assessed by the levels of glial ﬁbrillary acidic
protein (GFAP) and S100B (Esposito et al. 2007). CB2 receptors
also mediate anti-inﬂammatory actions of cannabinoids on
astrocytes (Sheng et al. 2005, 2009) and microglia (Correa,
Docagne, et al., 2009; Sagredo et al. 2009). The anti-in-
ﬂammatory effects of cannabinoids on glial cells involve the
inhibition of nuclear factor (NF) jB--induced transcription
(Curran et al. 2005; Zhang and Chen 2008; Kozela et al. 2010).
Estradiol and different estrogenic compounds also exert anti-
inﬂammatory effects on astrocytes and microglia by mecha-
nisms involving estrogen receptors (Arevalo et al. 2010). For
instance, estrogens decrease the expression of nitric oxide and
the inﬂammatory markers TNFa, IL-1b, IL-6, matrix metal-
loproteinase-9, and interferon-inducible protein-10 in cultured
astrocytes incubated with bacterial LPS (Kipp et al. 2007;
Tenenbaum et al. 2007; Lewis et al. 2008; Cerciat et al. 2010) by
mechanisms that, as for cannabinoids, involve the inhibition of
NFjB-induced transcription of proinﬂammatory chemokines
and cytokines (Dodel et al. 1999; Cerciat et al. 2010).
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Furthermore, estrogens decrease the number of reactive
astrocytes in vivo, after excitotoxic-induced neurodegenera-
tion (Ciriza et al. 2004), in experimental Parkinson’s disease
(Tripanichkul et al. 2006), in experimental diabetic central
neuropathy (Saravia et al. 2006), after lesion of the cholinergic
basal forebrain (Martinez and de Lacalle 2007), and after stab
wound brain lesions (Garcia-Estrada et al. 1993, 1999; Barreto
et al. 2007, 2009). Estrogens also reduce edema in injured brain
tissue by the enhancement of aquaporin-4 expression in
parenchymal reactive astrocytes and perivascular glial pro-
cesses (Tomas-Camardiel et al. 2005).
The similitude in the anti-inﬂammatory actions of cannabi-
noids and estrogens on astrocytes suggests a possible in-
teraction of these 2 families of molecules in the regulation
of reactive astroglia. To test this hypothesis, in this study, we
have assessed the effect of estradiol, the cannabinoid CB1
antagonist/inverse agonist AM251, and the cannabinoid CB2
antagonist/inverse agonist AM630 on reactive astroglia in the
cerebral cortex of male rats after a stab wound brain injury.
Materials and Methods
Animals and Experimental Treatments
Wistar albino male rats from the Complutense University animal colony
were kept on a 12:12-h light/dark schedule and received food and
water ad libitum. Animals were handled in accordance with the
guidelines published in the NIH Guide for the Care and Use of
Laboratory Animals, the principles presented in the Guidelines for the
Use of Animals in Neuroscience Research by the Society for
Neuroscience and following the European Union guidelines (Council
Directive 86/609/EEC). Experimental procedures were approved by
our institutional animal use and care committee. Special care was taken
to minimize suffering and to reduce the number of animals used to the
minimum required for statistical accuracy.
Brain Injury
Animals were anesthetized with halothane and placed in a stereotaxic
apparatus (David Kopf Instruments). In order to relieve postchirurgical
pain, animals received one intraperitoneal (i.p.) injection of buprenor-
phine (1 mg/kg; Buprex, Schering Plough) and one subcutaneous (s.c.)
injection of meloxicam (1 mg/kg; Metacam, Boehringer Ingelheim),
shortly after anesthesia induction. An incision of the scalp was made
and the cranium exposed. Then, a unilateral opening of the skull was
made with a dental drill. A 2.5-mm sterile sharp knife was introduced
vertically into the right cerebral hemisphere to a depth of 4.5 mm and
then removed. The rostral end of the knife was placed 2.5 mm posterior
to bregma and 1.1 mm lateral. The caudal end of the knife end was 5.0
mm posterior to bregma and 3.0 mm lateral. Coordinates were
determined according to the stereotaxic atlas of Paxinos and Watson
(1998). Bleeding was inhibited by compression with a hemostatic
gelfoam sponge.
Treatments with Estradiol and Cannabinoid Antagonists
Experiment 1
Immediately before brain injury, the animals received one of the
following treatments: 1) one i.p. injection of the vehicle for
cannabinoid antagonists (ethanol:cremophor EL:saline, 1:1:18; 1 mL/
kg), followed by one s.c. injection of the vehicle for 17b-estradiol (corn
oil; 1 mL/kg); 2) one i.p. injection of the vehicle for cannabinoid
antagonists, followed by one s.c. injection of 17b-estradiol (E2758,
Sigma-Aldrich; 1 mg/kg; 1 mL/kg); 3) one i.p. injection of the
cannabinoid CB1 antagonist/inverse agonist AM251 (Tocris Bioscience;
1 mg/kg; 1 mL/kg), followed by one s.c. injection of the vehicle for 17b-
estradiol; 4) one i.p. injection of the cannabinoid CB2 antagonist/
inverse agonist AM630 (Tocris Bioscience; 1 mg/kg; 1 mL/kg), followed
by one s.c. injection of the vehicle for 17b-estradiol; 5) one i.p. injection
of AM251, followed by one s.c. injection of 17b-estradiol; and 6) one i.p.
injection of AM630, followed by one s.c. injection of 17b-estradiol.
These treatments were repeated 24 and 48 h after brain injury. Thus,
the compounds were administered during the period of glial activation
(Garcia-Ovejero et al. 2002). The dose of estradiol selected in this study
is known to reduce reactive gliosis after stab wound brain injuries
(Barreto et al. 2007). This effect may be at least in part due to the high
levels of the steroid achieved shortly following the injections.
Experiment 2
In a second experiment, to assess the levels of the enzymes involved in
the synthesis and metabolism of cannabinoids and the expression of
cannabinoid receptors, sham-operated animals and animals that re-
ceived a stab wound injury were treated with estradiol or vehicle, as
described above. Seventy-two hours after surgery, animals were killed
by decapitation and the cerebral cortex around the injured area, and
the same cortical region of the right cerebral hemisphere from
noninjured controls was dissected and frozen.
Tissue Fixation and Immunohistochemistry
For histological analysis (experiment 1), 1 week after brain injury,
animals were deeply anaesthetized with pentobarbital (100 mg/kg,
Normon Veterinary Division) and perfused through the left cardiac
ventricle, ﬁrst with 50 mL saline solution (0.9% NaCl) and then with
250 mL ﬁxative solution (4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4). Brains were removed and immersed overnight at 4 C in
the same ﬁxative solution and then rinsed with phosphate buffer.
Coronal sections of the brain, 50 lm thick, were obtained using
a Vibratome (VT 1000 S, Leica Microsystems).
Immunohistochemistry was carried out on free-ﬂoating sections
under moderate shaking. All washes and incubations were done in 0.1
M phosphate buffer pH 7.4, containing 0.3% bovine serum albumin and
0.3% triton X-100. The endogenous peroxidase activity was quenched
for 10 min at room temperature in a solution of 3% hydrogen peroxide
in 30% methanol. After several washes in buffer, sections were
incubated overnight at 4 C with a monoclonal antibody for vimentin
(diluted 1:500; Clone V9, DAKO), a marker of reactive astrocytes, or
a monoclonal antibody for GFAP (diluted 1:1000; Clone GA5, Sigma-
Aldrich), a marker of reactive and resting astroglia. Sections were then
rinsed in buffer and incubated for 2 h at room temperature with
biotinylated goat antimouse immunoglobulin G (diluted 1:300; Pierce).
After several washes in buffer, sections were incubated for 90 min at
room temperature with avidin--biotin--peroxidase complex (diluted
1:250; ImmunoPure ABC peroxidase staining kit). The reaction product
was revealed by incubating the sections with 2 lg/mL 3,3#-diamino-
benzidine (Sigma-Aldrich) and 0.01% hydrogen peroxide in 0.1 M
phosphate buffer. Then, sections were dehydrated, mounted on
gelatinized slides, coverslipped, and examined with a Leica DMRB-E
microscope.
Morphometric Analysis
Only brains that showed a complete lesion from the dorsal to the
ventral limit of the cerebral cortex were selected for morphometry. All
morphometric analyses were performed on coded sections. The
number of vimentin immunoreactive cells was assessed within
a distance of 0--350 lm from the medial border of the wound (Zone
I). In addition, the number of GFAP immunoreactive cells was assessed
in 3 zones in the injured cortex: within a distance of 0--350 lm from the
medial border of the wound (Zone I), within a distance of 350--700 lm
from the medial border of the wound (Zone II), and within a distance of
700--1050 lm from the medial border of the wound (Zone III). The
number of GFAP immunoreactive cells was also evaluated in the
equivalent region of the contralateral noninjured cortex corresponding
to Zones I--III. The number of immunoreactive cells was estimated by
the optical disector method (Howard and Reed 1998) using total
section thickness for disector height (Hatton and von Bartheld 1999)
and a counting frame of 55 3 55 lm. A total of 78 counting frames were
assessed per animal and per each zone analyzed. Section thickness was
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measured using a digital length gauge device (Heidenhain-Metro MT
12/ND221) attached to the stage of a Leitz microscope. Cell nuclei
from immunoreactive cells that came into focus while focusing down
through the disector height were counted.
As an alternative method to evaluate glial reactivity, the surface
density of vimentin and GFAP immunoreactive cell bodies and cell
processes was assessed in the injured cerebral cortex in Zone II (350--
700 lm from the medial border of the wound). The surface density
of immunoreactive material was performed using a stereological grid,
according to the point-counting method of Weibel (1979). The ratio
of the surface of immunoreactive proﬁles to the reference volume
(surface density, Sv) was calculated by the following formula: Sv = 2I/L,
where I is the number of points at which the immunoreactive proﬁles
(vimentin or GFAP immunoreactive astroglial cell bodies and pro-
cesses) cross the test grid lanes and L is the test line length in the tissue
(Weibel 1979). The test grid used is based on the C16 grid of Weibel
(Weibel 1979) and has 10 3 10 lines of a total length of 2000 lm (L = 2
mm). Magniﬁcation was calculated with a calibrated slide (100 lines/
mm, Leitz). For each animal, a minimum of 2 sections were evaluated.
All immunoreactive proﬁles, whether heavily or less heavily labeled,
were considered for quantiﬁcation.
Messenger RNA Levels of the Enzymes Involved in
Endocannabinoid Synthesis and Metabolism and Messenger RNA
Levels of Cannabinoid Receptors
Total RNA was obtained from samples of the cerebral cortex
(experiment 2) using Trizol reagent (Gibco BRL Life Technologies)
according to the manufacturer’s instructions. Next, it was puriﬁed and
concentrated with RNeasy mini kit (Qiagen Hilden) with all RNA
samples showing A260/280 ratios between 1.9 and 2.1. One microgram
of RNA from each sample was reversed transcribed into complementary
DNA (cDNA) using random primer hexamers and a transcriptor reverse
transcriptase kit (Roche Applied Science) according to manufacturer’s
instructions. Negative control included reverse transcription reactions
omitting reverse transcriptase. The obtained cDNA was used as the
template for real-time quantitative polymerase chain reaction (PCR),
which was performed in an iCycler system (Bio-Rad) using the FastStart
Universal SYBR Green Mastermix (Roche Diagnostics). Primers for PCR
reaction (Sigma-Proligo France SAS) were designed based on NCBI
database sequences of rat reference messenger RNA (mRNA; Table 1)
and checked for speciﬁcity with BLAST software from NCBI website
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Each reaction was run in
duplicate and contained 2.5 lL of cDNA template, 5 mM Cl2Mg, and
0.4--0.5 lM of primers in a ﬁnal reaction volume of 15 lL. Cycling
parameters were 95 C for 5 min to activate DNA polymerase, then 35--
45 cycles of 95 C for 10 s to denature DNA, annealing temperature for
15 s (see Table 1), and a ﬁnal extension step of 72 C for 15 s in which
ﬂuorescence was acquired. Melting curves analysis and 1% agarose gel
electrophoresis were performed to ensure only a single product was
ampliﬁed. Gene expression was normalized to the expression of the
housekeeping gene b-actin and to the expression of SP1 gene. Similar
results were obtained with the 2 genes used for normalization. The data
shown in the ﬁgures correspond to the normalization using the SP1
gene.
Quantiﬁcation was carried out with a standard curve that was run at
the same time as the sample with each dilution in duplicate. The
standards were a puriﬁed and quantiﬁed PCR product, serially diluted.
Brieﬂy, to obtain them, puriﬁed RNA from a tissue known to express
the target gene was retrotranscribed to cDNA and PCR ampliﬁed by
using speciﬁc primers pair (see Table 1). The obtained PCR product
was puriﬁed by using a high pure PCR product puriﬁcation kit (Roche
Diagnostic), quantiﬁed by 260-nm absorbance, and serially diluted to
10
–6 pg/lL. An aliquot of the undiluted PCR product was run in a 1%
agarose gel electrophoresis for checking the fragment size and the
absence of other contaminant fragments. Eight 10-fold dilutions (10
+1
to 10
–6 pg/lL) were checked for optimal cycling on the iCycler system
and 5 or 6 of them selected for running the standard curve.
Statistical Analysis
The n used for statistical analysis was the number of animals and it is
indicated in the ﬁgure legends. Because the Levene’s test revealed that
the data do not meet the assumption of normality, the nonparametric
Kruskal--Wallis test was used for statistical analysis followed by the
Dunn’s method, with P < 0.05 considered to be signiﬁcant.
Results
Effect of Estradiol and CB Receptor Antagonists on
Reactive Astrogliosis
The qualitative inspection of the sections immunostained for
vimentin revealed a prominent glial scar along the borders of
the wound (Fig. 1). Qualitative differences were observed
between the different experimental groups. Animals treated
with estradiol alone (Fig. 1B) showed a glial scar with a lower
cellular density compared with control animals (Fig. 1A) and
with animals injected with estradiol and either the CB1
Table 1
Oligonucleotides used for quantitative PCR
Gene Primer sequences Annealing temperature
(C)
GenBank accession
number
SP1 5#-AGCAGGATGGTTCTGGTCAA-3# 54.0 NM_012655.1
5#-AGGTGATGTTCCCATTCAGG-3#
b-Actin 5#-CAGGCTGTGTTGTCCCTGTA-3# 51.4 NM_031144.2
5#-GCTGTGGTGGTGAAGCTGTA-3#
DAGLa 5#-GGGTACCTAATGGCTGCTCA-3# 60.5 NM_001005886.1
5#-AGGACTGACCATCCAACCTG-3#
NAPE-PLD 5#-GGAGCTTATGAGCCAAGGTG-3# 57.0 AB112351
5#-ACTCTCCGTGCTTCAGGATG-3#
FAAH 5#-GTTACAGAGTGGAGAGCTGTC-3# 46.5 NM_024132.3
5#-GAGGGTTACTGCAGTCAAAGC-3#
MAGL 5#-CATGGAGCTGGGGAACACTG-3# 58.1 NM_138502.1
5#-GGAGATGGCACCGCCATGGAG-3#
CB1 5#-AGACCTCCTCTACGTGGGCTCG-3# 62.0 NM_012784.2
5#-GTACAGCGATGGCCAGCTGCTG-3#
CB2 5#-GCAGCCTGCTGCTGACTGCTG-3# 58.9 NM_020543.3
5#-TGCTTTCCAGAGGACATACCC-3#
Figure 1. Representative images of the injured cerebral cortex showing examples of
vimentin immunoreactivity after the administration of vehicles (A), estradiol (B),
estradiol and the CB1 receptor antagonist AM251 (C), and estradiol and the CB2
receptor antagonist AM630 (D). Asterisks indicate the border of the lesion. Insets
show details of vimentin immunoreactive cells at high magnification. Dotted lines
delimit the regions of the cerebral cortex in proximity of the border of the wound
where the number of vimentin immunoreactive cells (Zone I) and the surface density
of vimentin immunoreactive material (Zone II) were evaluated. Scale bar represents
200 lm for main figures and 50 lm for insets.
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receptor antagonist (Fig. 1C) or the CB2 receptor antagonist
(Fig. 1D).
By means of the morphometric analysis, estradiol adminis-
tration resulted in a signiﬁcant decrease in the number of
immunoreactive cells (Fig. 2) and in the surface density of
vimentin immunoreactive material (Fig. 3) compared with
control values. The cannabinoid receptor antagonists, per se,
did not signiﬁcantly affect vimentin immunoreactivity com-
pared with control values. However, the animals injected with
estradiol and either the CB1 or the CB2 receptor antagonist
showed a number of vimentin immunoreactive cells and
a surface density of vimentin immunoreactive material that
was not signiﬁcantly different from control values (Figs. 2 and
3). This indicates that both cannabinoid receptor antagonists
blocked the effect of estradiol on reactive astrogliosis.
Similar results were observed in the sections immunostained
for GFAP (Figs. 4 and 5). GFAP immunoreactive cells in the
border of the lesion were of smaller size in the animals treated
with estradiol alone than in the other experimental groups
(Fig. 5). In addition, the morphometric analysis of cortical
Zones I--III revealed a signiﬁcant decrease in the number of
GFAP immunoreactive cells (Fig. 6) in the animals treated with
estradiol compared with control animals. In control animals,
the number of GFAP immunoreactive cells progressively
decreased with the distance from the border of the wound.
However, the number of GFAP immunoreactive cells was
signiﬁcantly higher in Zones I--III of the injured cortex than in
the corresponding region of the contralateral noninjured
cortex. In contrast, in the animals treated with estradiol, the
number of GFAP immunoreactive cells reached similar values in
Zone III than in the contralateral cortex. In agreement with the
estimation of the number of GFAP immunoreactive cells, the
surface density of GFAP immunoreactive material in Zone II
also showed a signiﬁcant decrease in the animals treated with
estradiol (Fig. 7). The cannabinoid receptor antagonists, per se,
did not signiﬁcantly affect the surface density and the number
of GFAP immunoreactive cells compared with control values.
However, the animals injected with estradiol and either the
CB1 or the CB2 receptor antagonist showed a surface density
of GFAP immunoreactive material and a number of GFAP
immunoreactive cells that was not signiﬁcantly different from
control values (Figs. 6 and 7). None of the treatments induced
a signiﬁcant change in the number of GFAP immunoreactive
cells in the noninjured cortex.
Effect of Brain Injury and Estradiol Treatment on the
mRNA Levels of Enzymes Involved in Endocannabinoid
Synthesis and Metabolism
Brain injury resulted in a signiﬁcant decrease in the mRNA
levels of monoacylglycerol lipase (MAGL; Fig. 8) and N-acyl
phosphatidylethanolamine phospholipase D (NAPE-PLD; Fig. 9)
in the injured cerebral cortex, compared with the control
noninjured cortex. However, injured animals injected with
estradiol did not displayed decreased mRNA levels of MAGL
(Fig. 8) and NAPE-PLD (Fig. 9). Estradiol did not affect the
mRNA levels of these enzymes in noninjured cerebral cortex.
The mRNA levels of diacylglycerol lipase (DAGL) and fatty acid
amidohydrolase (FAAH) in the cerebral cortex were unaffected
by brain injury and by estradiol treatment (data not shown).
Effect of Brain Injury and Estradiol Treatment on the
mRNA Levels of Cannabinoid Receptors
The mRNA levels of CB1 and CB2 receptors in the cerebral
cortex were not signiﬁcantly affected by brain injury. Estradiol
was unable to modify CB1 receptor mRNA levels in the control
and the injured cortex (data not shown). In contrast, estradiol
treatment resulted in a signiﬁcant increase in the mRNA levels
of CB2 receptors in the injured cortex (Fig. 10).
Discussion
Previous studies have shown that the systemic administration
of estradiol to male rats signiﬁcantly decreases reactive
astrogliosis after a stab wound in the brain (Barreto et al.
Figure 2. Number of vimentin immunoreactive astrocytes per cubic millimeter within
a distance of 350 lm from the medial border of the wound (Zone I) in animals
injected with vehicles (controls, C; n 5 6), estradiol (E; n 5 6), the CB1 receptor
antagonist AM251 (ACB1; n 5 6), the CB2 receptor antagonist AM630 (ACB2; n 5
6), estradiol and the CB1 receptor antagonist AM251 (E þ ACB1; n 5 6), and
estradiol and the CB2 receptor antagonist AM630 (E þ ACB2; n 5 6). Data are
mean þ standard error of the mean (SEM). *, significant difference versus control
values (P\ 0.05).
Figure 3. Surface density of vimentin immunoreactive material within a distance of
350--700 lm from the medial border of the wound (Zone II) in animals injected with
vehicles (controls, C; n 5 6), estradiol (E; n 5 6), the CB1 receptor antagonist
AM251 (ACB1; n5 6), the CB2 receptor antagonist AM630 (ACB2; n5 6), estradiol
and the CB1 receptor antagonist AM251 (E þ ACB1; n 5 6), and estradiol and the
CB2 receptor antagonist AM630 (E þ ACB2; n 5 6). Data are mean þ SEM. *,
significant difference versus control values (P\ 0.05).
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2007). Our present results conﬁrm these previous observations.
Estradiol reduced the surface density and the number of
astrocytes labeled with vimentin, a marker of reactive
astrocytes. These changes were conﬁrmed using GFAP,
a marker of resting and reactive astrocytes. Estradiol signiﬁ-
cantly decreased the surface density and number of GFAP
immunoreactive astrocytes in the injured cortex. In addition, in
the animals treated with estradiol, the number of GFAP
immunoreactive cells reached the levels of the noninjured
cortex at a distance of 700--1050 lm from the medial border of
Figure 4. Representative images of the injured cerebral cortex showing examples of GFAP immunoreactivity after the administration of vehicles (A,E), estradiol (B,F), estradiol
and the CB1 receptor antagonist AM251 (C,G), and estradiol and the CB2 receptor antagonist AM630 (D,H). The regions demarcated by squares in panels E--H are shown at high
magnification in Figure 5. Dotted lines delineate the 3 zones in which the number of GFAP immunoreactive cells was evaluated. Asterisks indicate the border of the lesion. Scale
bar represents 600 lm for panels A--C and 350 lm for panels E--H.
Figure 5. Detail of GFAP immunoreactive cells in the proximity of the border of the lesion (the location is indicated in Fig. 4). (A) Animal treated with vehicles. (B) Animal injected
with estradiol. (C) Animal injected with estradiol and the CB1 receptor antagonist AM251. (D) Animal injected with estradiol and the CB2 receptor antagonist AM630. Asterisks
indicate the border of the lesion. Scale bar, 100 lm.
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the wound. In contrast, in control animals, although GFAP
immunoreactive cells also progressively decreased with the
distance to the injury, their number was still signiﬁcantly
higher at a distance of 700--1050 lm from the medial border of
the wound than in the contralateral cortex.
Under physiological conditions, estradiol regulates GFAP
expression in astrocytes by a mechanism involving an estrogen
response element on the GFAP gene promoter (Stone et al.
1998). In addition, estradiol may indirectly reduce the number
of vimentin and GFAP immunoreactive astrocytes after brain
injury by affecting the process of glial activation, for instance,
by controlling glial cell proliferation (Garcia-Estrada et al. 1993,
1999) and the synthesis and release of proinﬂammatory
cytokines (Arevalo et al. 2010). Therefore, although estradiol
directly regulates GFAP expression and may also potentially
regulate vimentin expression by direct mechanisms, the
possibility exists for an interaction with other factors that
regulate reactive gliosis to reduce the number of vimentin and
GFAP immunoreactive astrocytes after brain injury. Among
these factors, our ﬁndings suggest that endocannabinoids may
be involved in the antigliotic effect of estradiol, since the
antagonism of both cannabinoid CB1 and CB2 receptors
reduced the estrogenic effect on reactive astroglia.
Figure 6. Number of GFAP immunoreactive astrocytes per cubic millimeter within
distances of 0--350 lm (Zone I), 350--700 lm (Zone II), and 700--1050 lm (Zone III)
from the medial border of the wound and in the equivalent region of the contralateral
noninjured cortex. C, control animals injected with vehicles (n 5 6); E, animals
injected with estradiol (n 5 6); ACB1, animals injected with the CB1 receptor
antagonist AM251 (n 5 6); ACB2, animals injected with the CB2 receptor antagonist
AM630 (n 5 6); E þ ACB1, animals injected with estradiol and the CB1 receptor
antagonist AM251 (n 5 6); and E þ ACB2, animals injected with estradiol and the
CB2 receptor antagonist AM630 (n 5 6). Data are mean þ SEM. *, significant
differences versus control values (P\ 0.05) and §, significant differences versus the
contralateral cortex (P\ 0.05).
Figure 7. Surface density of GFAP immunoreactive material within a distance of
350--700 lm from the medial border of the wound (Zone II) in animals injected with
vehicles (controls, C; n 5 6), estradiol (E; n 5 6), the CB1 receptor antagonist
AM251 (ACB1; n 5 6), the CB2 receptor antagonist AM630 (ACB2; n 5 6), estradiol
and the CB1 receptor antagonist AM251 (E þ ACB1; n 5 6), and estradiol and the
CB2 receptor antagonist AM630 (E þ ACB2; n 5 6). Data are mean þ SEM. *,
significant differences versus control values (P\ 0.05).
Figure 9. Levels of mRNA of NAPE-PLD normalized to the levels of mRNA for SP1
gene in the right cerebral cortex from animals that received a stab wound brain injury
and from control noninjured animals. C, cerebral cortex from control noninjured
animals injected with vehicle (n 5 6); E, cerebral cortex from control noninjured
animals injected with estradiol (n 5 5); I, injured cortex from animals injected with
vehicle (n 5 5); and I þ E, injured cortex from animals that were treated with
estradiol (n5 4). Data are means þ SEM. *, significant difference (P\ 0.05) versus
noninjured cortex.
Figure 8. Levels of mRNA of MAGL normalized to the levels of mRNA for SP1 gene in
the right cerebral cortex from animals that received a stab wound brain injury and from
control noninjured animals. C, cerebral cortex from control noninjured animals injected
with vehicle (n 5 5); E, cerebral cortex from control noninjured animals injected with
estradiol (n5 5); I, injured cortex from animals injected with vehicle (n5 5); and Iþ E,
injured cortex from animals that were treated with estradiol (n5 4). Data are meansþ
SEM. *, significant difference (P\ 0.05) versus noninjured cortex.
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Although the antagonists of cannabinoid receptors blocked
the effect of estradiol, they did not have an effect per se on the
number of reactive astrocytes. This suggests that the endoge-
nous cannabinoid tone does not affect reactive astrogliosis in
our model. However, our results also suggest that estradiol may
reduce reactive astroglia by regulating the activity of the
endocannabinoid system in the brain (Rodrı´guez de Fonseca
et al. 1994; Corchero et al. 2001; Bradshaw et al. 2006; Nguyen
and Wagner 2006; Amantea et al. 2007; Hill et al. 2007). Indeed,
our ﬁndings indicate that estradiol blocks the decrease caused
by injury in the mRNA levels of MAGL and NAPE-PLD in the
cerebral cortex. MAGL is involved in the metabolism of 2-
arachidonoylglycerol (2-AG) and NAPE-PLD participates in the
synthesis of AEA (Basavarajappa 2007). Therefore, estradiol
partially counteracts the effect of brain injury on the enzymes
that participate in the synthesis of endocannabinoids. By this
action, estradiol may regulate the levels of 2-AG and AEA in the
injured cerebral cortex.
The increase in the mRNA levels of CB2 receptors in the
injured cerebral cortex of animals treated with estradiol
suggests that the hormone may also affect the intercellular
signaling of endocannabinoids by the modiﬁcation of cannabi-
noid receptors. An interaction may occur in the signaling
downstream of cannabinoid receptors as well, since both
estradiol and cannabinoids regulate the activity of the mitogen-
activated protein kinase and the phosphatidylinositol-3 kinase/
Akt pathways, which are involved in the control of the
inﬂammatory response (Molina-Holgado, Molina-Holgado,
et al. 2002; Dı´az-Laviada and Ruiz-Llorente 2005; Mendez
et al. 2006; Marin et al. 2009). Estradiol may also interact with
cannabinoid receptors in the regulation of protein kinase A and
NO generation in neural cells (Dina et al. 2001; Kim et al. 2006).
Both CB1 and CB2 receptors appear to be involved in the
action of estradiol in the control of reactive gliosis, since both
cannabinoid receptor antagonists increased the surface density
and number of reactive astrocytes in estradiol treated rats to
values not signiﬁcantly different from those of control animals.
The interaction of estradiol and cannabinoids may occur
directly on reactive astrocytes, since these cells express
estrogen receptors and cannabinoid receptors (Garcia-Ovejero
et al. 2002, 2009; Stella 2010). Indeed, both cannabinoid
receptor agonists and estrogens regulate intracellular Ca2
+
levels in astrocytes (Chaban et al. 2004; Navarrete and Araque
2008; Bondar et al. 2009) and decrease reactive gliosis by the
inhibition of NFjB mediated transcription (Dodel et al. 1999;
Curran et al. 2005; Sheng et al. 2005; Zhang and Chen 2008;
Leichsenring et al. 2009; Cerciat et al. 2010; Kozela et al. 2010).
In addition, cannabinoids and estradiol regulate astrocyte--
astrocyte and astrocyte--neuron communication (Venance et al.
1995; Rao and Sikdar 2006, 2007; Navarrete and Araque 2008),
which may also participate in the activation of astrocytes.
Cannabinoids and estradiol may also regulate reactive
astrogliosis by indirect effects on microglia (Waksman et al.
1999; Puffenbarger et al. 2000; Ramı´rez et al. 2005; Vegeto et al.
2006; Barreto et al. 2007; Tapia-Gonzalez et al. 2008; Correa,
Docagne, et al. 2009; Kreutz et al. 2009; Sagredo et al. 2009;
Luongo et al. 2010). Among other possibilities, estradiol may
control reactive astrogliosis by the regulation of CB1 receptor
signaling in astrocytes and exert an additional control mediated
by CB2 receptors expressed in microglia (Correa, Docagne,
et al. 2009; Romero-Sandoval et al. 2009; Sagredo et al. 2009;
Correa et al. 2010; Luongo et al. 2010). In this regard, the
increase in the mRNA levels of CB2 receptors induced by
estradiol may be associated with an increase in CB2 receptor
signaling, which is known to result in the reduction of the
proinﬂammatory phenotype of microglia (Correa, Docagne,
et al. 2009; Romero-Sandoval et al. 2009; Sagredo et al. 2009;
Correa et al. 2010; Luongo et al. 2010). Further studies should
determine the role of the direct and indirect mechanisms and
the cell types involved in the regulation of reactive astrogliosis
by estradiol through cannabinoid receptors. In addition, the
possible involvement of cannabinoid receptors in the regula-
tion of gliosis exerted by other steroid hormones, such as
testosterone and progesterone, merits to be examined.
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